Jazz Pharmaceuticals plc
http://jazzpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jazz Pharmaceuticals plc
UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy
Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.
Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus
The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.
In Vivo’s Deals Of The Year 2021: Cast Your Vote!
It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
The Top Five (Non-COVID) Pharma Stories Of 2021
The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.
Company Information
- Industry
- Biotechnology
- Contract Manufacturing Organization
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Alizé Pharma II
- Azur Pharma Public Limited Company
- Cavion, Inc.
- Cavion LLC (Tau Therapeutics LLC
- Xdynia LLC)
- Celator Pharmaceuticals, Inc.
- Gentium S.p.A.
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals Ireland Limited
- Orphan Medical, Inc.